Tailing pharmaceutical 1.1 new drug - alternative Library of "major new drug creation" special project of the Ministry of science and technology
-
Last Update: 2015-04-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Thaling pharmaceutical announced that the national 1.1 new drug, xitique [niacin (Yuetai) injection], applied by the group for the treatment of "myelodysplastic syndrome (MDS)" and industrial transformation research project has been included in the "major new drug creation" special project alternative database of the Ministry of science and technology of the people's Republic of China Tailing Pharmaceutical (Group) Co., Ltd., headquartered in Hong Kong, formally entered the Chinese mainland pharmaceutical market on August 22, 1995 After ten years, it has developed into a group company integrating research and development, production, distribution and professional promotion of pharmaceutical products.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
